What Happened?
Waltham, MA-based Corvidia Appointed Michael Davidson as Chief Executive Officer
About the Company
Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company`s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia`s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways. This approach confers unique concepts within the field of cardiovascular medicines and an unprecedented accelerated path-to-market. Corvidia brings together a team of distinguished scientists, experienced drug developers as the management team, and a successful group of investors. Corvidia is headquartered in the Greater Boston area.
About the Person
Michael Davidson is a founder and serves as the Chief Executive Officer of Corvidia Therapeutics and a member of the Board. Michael is a leading expert in the field of Lipidology and was named in The Best Doctors in America for the past 10 years. Michael was the co-founding Chief Medical Officer of Omthera Pharmaceuticals in 2008 that was acquired by Astra Zeneca Pharmaceutical in 2013 for $443M. He also founded the Chicago Center for Clinical Research, which became the largest investigator site in the United States and was acquired by Pharmaceutical Product Development in 1996. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Michael is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association (2010-2011). Michael received his BA/MS from Northwestern University and MD from The Ohio State University School of Medicine.
Info Source
Press Release
Short Profile